Novartis is ramping up its hematology research activities. The pharmaceutical company acquired the US Selexys Pharmaceutical.
The purchase price could reach 665 million dollars (671 million francs). This acquisition comes after the results obtained in phase 2 of the clinical trial with the compound SelG1, an experimental treatment to treat and soothe the pain crises of patients with sickle cell anemia, also called sickle cell anemia.
In 2013, about 3.2 million people had sickle cell disease, while another 43 million had sickle cell trait.
Related news: Kymos Pharma buys Pharmaprogress
